Aetion and Cegedim Health Data have announced plans to collaborate on technology integrating real-world data (RWD) culled from European sources into trial technology. The collaboration involves integration of Cegedim’s THIN (The Health Improvement Network) European RWD into the Aetion Evidence Platform (AEP).
According to Aetion, the AEP analyzes a range of data—including claims, electronic health records (EHRs), registries, and clinical-trial data—to help produce transparent, rapid, and scientifically-validated real world evidence (RWE) on the safety, effectiveness, and value of medical interventions.
The partnership is intended to empower pharma and biopharma companies, top payers and regulatory agencies to use RDW to uncover new insights about therapies. The THIN data anonymized EHRs from France, UK, Spain, Belgium and Romania, with detail on diagnoses, treatments, clinical outcomes and interventions; it is intended to deliver a robust view of treatment use and outcomes.
Carolyn Magill, CEO of Aetion, said the pharmaceutical development industry must overcome challenges created by the coronavirus pandemic.
“Over the last few months, COVID-19 has changed the drug development landscape, as leading biopharma companies, regulators, and health technology assessment bodies (HTAs) alike look to real world data to urgently answer questions on treatment utilization, safety, and effectiveness,” she said. “Through this partnership with Cegedim, our aim is to help global biopharma companies quickly generate decision-grade real-world evidence by expanding our data sources and capabilities in the EU.”
Gilles Paubert, global head of Cegedim Health Data, commented that companies can benefit from collaborations such as his, to achieve advancements in development.
“The clinically rich data that we capture through THIN, which has a history dating back to 1994, will help clients using Aetion’s platform explore the nuance of each particular dataset, be it therapeutic area-specific or region-specific, to reveal critical insights needed to bring a new drug to market and deliver efficacious treatments to patients faster,” Paubert said.
Use of RWE is on the rise as stakeholders along the drug development chain strive to accelerate discovery of therapies while overcoming challenges created by the pandemic. The European Medicines Agency (EMA) has announced plans to incorporate RWD to complement evidence from clinical trials and to help streamline regulatory and decision-making processes for COVID-19 vaccine development and authorization.